News & Updates

Researchers from the University College London (UCL) in the UK have developed a high-resolution three-dimensional (3D) photoacoustic scanner based on the Fabry-Perot (FP) ultrasound sensor concept and examined its potential as a tool for clinical vascular imaging.

Oral semaglutide, when used in routine clinical practice, appears effective in managing type 2 diabetes (T2D) even in “very elderly” populations.

Treatment with tirzepatide reduced the risk of cardiovascular (CV) death and worsening heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) and obesity, according to the SUMMIT trial presented at AHA 2024.

A study investigating the association between the risk of myasthenia gravis (MG) and statin therapy found the risk of onset in patients with no prior history of MG and the risk of exacerbation among patients with pre-existing MG were the highest in the first month after initiating statins.

In patients with type 2 diabetes (T2D), treatment with empagliflozin has a null effect on the risk of nonproliferative diabetic retinopathy (NPDR) compared with a DPP-4 inhibitor but may confer protection against DR progression, according to a study.

Lifestyle interventions, including diet and exercise, can help lower serum sphingolipid species associated with insulin resistance, suggest the results of a recent study.

Intensive systolic blood pressure (BP)-lowering treatment to reach target levels of less than 120 mm Hg is more beneficial than standard treatment in terms of reducing the risk of major cardiovascular events in Chinese patients with type 2 diabetes (T2D) and elevated BP, according to data from the BPROAD* trial.